XtalPi Introduces AI-Powered XGlue Platform for Molecular Glue Drug Discovery

February 02, 2026
XtalPi unveiled its new AI-driven XGlue platform at the 2026 International Symposium on Molecular Glue Drug Discovery in Shanghai, aiming to accelerate systematic discovery of molecular glue therapeutics.

XtalPi unveiled its AI-driven XGlue platform at the 2026 International Symposium on Molecular Glue Drug Discovery in Shanghai, announced in a press release. The event gathered scientists, biopharma innovators, and investors to discuss advances in targeting previously undruggable proteins.

XGlue integrates physics-based AI modeling with an autonomous synthesis workflow to form a closed-loop design–make–test system. This setup allows rapid iteration and expands the range of potential targets for molecular glue therapeutics.

Speakers from institutions including Stanford University, EPFL, and the Chinese Academy of Sciences presented research on computational design and rational discovery of molecular glues for diseases with unmet medical needs. Industry participants from companies such as Sanofi and Betta Pharma joined discussions on improving collaboration between academic research, industrial development, and clinical applications.

The symposium concluded with consensus on the importance of integrating AI, robotics, and cross-sector partnerships to advance protein degradation and accelerate the translation of molecular glue therapies into clinical use.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Life Sciences

02/02
Oracle Launches AI Data Platform for Life Sciences Research
02/02
Nucs AI Forms Medical Advisory Board for AI-Driven Theranostics
02/02
Healthcare Triangle Partners with Better.care to Expand Health Data Platforms Across EMEA
01/28
Viveka Health Earns HITRUST e1 Certification with Support from Palindrome Technologies
01/21
EyeContactDX Appoints Dr. Carol Weitzman as Senior Strategic Advisor for AI Autism Screening

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Market report

Superagency in the Workplace: Empowering People to Unlock AI’s Full Potential

This report explores the transformative potential of artificial intelligence in the workplace, emphasizing the readiness of employees versus the slower adaptation of leadership. It highlights the significant productivity growth potential AI offers, akin to historical technological shifts, and discusses the barriers to achieving AI maturity within organizations. The report also examines the role of leadership in steering companies towards effective AI integration and the need for strategic investments to harness AI's full capabilities.

Read more

You May Also Like